VYNE Announces Merger with Yarrow Bioscience, Focuses on TSHR Antibody

 

• VYNE Therapeutics (VYNE, Financial) is merging with Yarrow Bioscience, forming Yarrow Bioscience, Inc., with a focus on YB-101 for treating Graves' Disease and Thyroid Eye Disease.
• A $200 million investment led by RTW Investments will support Yarrow's operations until 2028, facilitating clinical trials for YB-101.
• VYNE shareholders will receive a cash dividend and retain a 3% stake in the new entity, with the merger expected to complete in Q2 2026.

VYNE Therapeutics (VYNE) is set to merge with Yarrow Bioscience through an all-stock transaction, forming a new entity to be named Yarrow Bioscience, Inc. This combined company will trade under the ticker "YARW" on Nasdaq. The primary focus post-merger will be on YB-101, a promising clinical-stage TSHR antibody intended for treating Graves' Disease (GD) and Thyroid Eye Disease (TED).

https://www.gurufocus.com/news/4073477/vyne-announces-merger-with-yarrow-bioscience-focuses-on-tshr-antibody-development